» Articles » PMID: 32100478

Relationship Between Pancreatic Cancer-associated Diabetes and Cachexia

Overview
Date 2020 Feb 27
PMID 32100478
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Pancreatic cancer-associated diabetes mellitus (PCDM) is a paraneoplastic phenomenon characterized by worsening hyperglycaemia and weight loss. Galectin-3 and S100A9, mediators of PCDM, have pro-inflammatory functions and might thereby induce systemic inflammation and cachexia. We aimed to examine whether PCDM directly mediates cachexia.

Methods: Consecutive pancreatic cancer (PC) patients with and without PCDM (n = 88 each) with complete information were included. Cachexia was defined as weight loss >5% within 6 months or weight loss >2% and body mass index <20 kg/m or sarcopenia. Skeletal muscle mass was measured with lumbar skeletal muscle index (SMI) using computed tomography images. Cachexia-related parameters (prevalence of cachexia, weight loss, and SMI) were compared between patients with and without PCDM. Relations between cachexia-related parameters and fasting blood glucose or serum levels of galectin-3 and S100A9 were analysed by Spearman correlation and logistic regression analyses.

Results: One hundred two (58.0%) patients had cachexia at diagnosis. No significant differences existed between patients with and without PCDM in prevalence of cachexia (64.8% vs. 51.1%, P = 0.093), percentage of weight loss (median 6.8 vs. 4.0, P = 0.085), and SMI (median 45.8 vs. 45.3 cm /m in men, P = 0.119; 34.9 vs. 36.3 cm /m in women, P = 0.418). In patients with cachexia, the percentage of weight loss and SMI were also similar between patients with and without PCDM. In patients with PCDM, fasting blood glucose was comparable between patients with and without cachexia (P = 0.458) and did not correlate with the percentage of weight loss (P = 0.085) or SMI (P = 0.797 in men and 0.679 in women). Serum S100A9 level correlated with fasting blood glucose (correlation coefficient 0.213, P = 0.047) but not with the percentage of weight loss (P = 0.977) or SMI (P = 0.247 in men and 0.458 in women). Serum galectin-3 level also did not correlate with the percentage of weight loss (P = 0.226) and SMI (P = 0.201 in men and 0.826 in women). Primary tumour size was associated with cachexia (adjusted odds ratio per 1 cm increase 1.28, 95% confidence interval 1.02-1.60, P = 0.034), whereas PCDM, fasting blood glucose, and levels of galectin-3 and S100A9 were not predictors of cachexia.

Conclusions: Neither fasting blood glucose nor levels of galectin-3 and S100A9 were associated with cachexia-related parameters. Mediators of PCDM and hyperglycaemia do not directly mediate PC-induced cachexia.

Citing Articles

Impact of Cachexia on Chemotherapy Efficacy and Survival in Pancreatic Cancer: A Systematic Review and Meta-Analysis.

Khalil M, Jafri S, Naqvi M, Jauhar I, Kumar V, Ali S Cancer Control. 2024; 31:10732748241292784.

PMID: 39397738 PMC: 11483828. DOI: 10.1177/10732748241292784.


Remnant Pancreas Volume Affects New-Onset Impaired Glucose Homeostasis Secondary to Pancreatic Cancer.

Yang J, Tan C, Liu Y, Zheng Z, Liu X, Chen Y Biomedicines. 2024; 12(8).

PMID: 39200119 PMC: 11351567. DOI: 10.3390/biomedicines12081653.


Leveraging real-world data to predict cancer cachexia stage, quality of life, and survival in a racially and ethnically diverse multi-institutional cohort of treatment-naïve patients with pancreatic ductal adenocarcinoma.

Permuth J, Park M, Chen D, Basinski T, Powers B, Gwede C Front Oncol. 2024; 14:1362244.

PMID: 39109281 PMC: 11300308. DOI: 10.3389/fonc.2024.1362244.


Triglyceride-glucose index and glycemic dynamics in pancreatic ductal adenocarcinoma: implications for disease progression and prognosis.

Song Y, Jiang L, Han Y, Zhang S, Li S J Transl Med. 2024; 22(1):708.

PMID: 39080703 PMC: 11290143. DOI: 10.1186/s12967-024-05524-w.


Defining and Addressing Research Priorities in Cancer Cachexia through Transdisciplinary Collaboration.

Park M, Whelan C, Ahmed S, Boeringer T, Brown J, Crowder S Cancers (Basel). 2024; 16(13).

PMID: 39001427 PMC: 11240731. DOI: 10.3390/cancers16132364.


References
1.
Mayers J, Wu C, Clish C, Kraft P, Torrence M, Fiske B . Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med. 2014; 20(10):1193-1198. PMC: 4191991. DOI: 10.1038/nm.3686. View

2.
Berdeaux R, Hutchins C . Anabolic and Pro-metabolic Functions of CREB-CRTC in Skeletal Muscle: Advantages and Obstacles for Type 2 Diabetes and Cancer Cachexia. Front Endocrinol (Lausanne). 2019; 10:535. PMC: 6688074. DOI: 10.3389/fendo.2019.00535. View

3.
Mitsiopoulos N, Baumgartner R, Heymsfield S, Lyons W, Gallagher D, Ross R . Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol (1985). 1998; 85(1):115-22. DOI: 10.1152/jappl.1998.85.1.115. View

4.
Bachmann J, Heiligensetzer M, Krakowski-Roosen H, Buchler M, Friess H, Martignoni M . Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg. 2008; 12(7):1193-201. DOI: 10.1007/s11605-008-0505-z. View

5.
Singh S, Paul Singh P, Singh A, Murad M, McWilliams R, Chari S . Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Am J Gastroenterol. 2013; 108(4):510-9. DOI: 10.1038/ajg.2013.7. View